Can we target KRAS effectively in advanced NSCLC?

Can we target KRAS effectively in advanced NSCLC?

Da: GRACEcast
0 0 7 anni fa
Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

Seguici su Facebook